PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New womb cancer test could prevent need for invasive diagnostic procedures

The WID-qEC test successfully identified 91% of womb cancer cases.

Researchers from University College London (UCL) and the University of Innsbruck have revealed that a new test to detect womb cancer could prevent 87% of women from needing an invasive diagnostic procedure.

The new test could accelerate and simplify the diagnosis of womb cancer or rule the condition out as a cause of symptoms.

Published in The Lancet Oncology and funded by the Eve Appeal, the European Research Council and Land Tirol, the WID-qEC test took samples from 400 peri- and post-menopausal women being investigated at the UCL hospital gynaecological rapid access clinic with abnormal vaginal bleeding, which identified 12 women with womb cancer.

WID-qEC searches for DNA methylation ‘tags’ to identify DNA from cancer cells to determine whether cancer is present or not in the womb.

Patients in the UK with abnormal vaginal bleeding are currently offered a transvaginal ultrasound, a scanner probe inserted into the vagina to visualise the inside of the womb, or other techniques to identify thickened womb lining (endometrium) prior to a biopsy.

To collect the biopsy, a hysteroscopy, an invasive and sometimes painful process using a narrow telescope with a camera that enters the womb, is performed, followed by a biopsy.

After performing 603 imaging tests, researchers found that 40% of patients needed more than one imaging test to decide their next steps and 75 women without cancer needed a follow-up with a surgical diagnostic procedure following endometrial thickness measurements.

The WID-qEC test identified 91% of womb cancer cases and identified positive test results in only ten women without cancer.

Professor Martin Widschwendter from the UCL EGA Institute for Women’s Health and the University of Innsbruck said: “The WID-qEC test… significantly reduces the complexity of the pathway which women, presenting with abnormal bleeding, currently have to undergo.

“The test will be commercially available in Austria and Switzerland from early 2024 and [the team] are actively working towards commercialisation in other countries including the UK in the coming months.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026